CryoLife president and chief executive officer Steven Anderson said, "We believe that this acquisition is well in-line with our cardiovascular focus and look forward to integrating the business and collaborating with the Hemosphere team to train our sales reps on the HeRO Graft."
HeRO Graft is a vascular access device which is used as an alternative for patients using catheters for end-stage renal disease Hemodialysis and is implanted completely under the skin, which reduces infection risk.
The HeRO Graft is clinically proven to maintain long-term access for hemodialysis patients with venous outflow obstruction.
CryoLife distributes CryoValve SG pulmonary heart valve, CryoPatch SG pulmonary cardiac patch, BioGlue Surgical Adhesive, PerClot and BioFoam Surgical Matrix.
